JNJ-7706621 (JNJ7706621)，一种可渗透细胞的三唑基磺酰胺化合物，是ATP竞争性、可逆的Aurora激酶和CDK抑制剂，作用于CDK1/2和Aurora-A/B的IC₅₀为9 nM、3 nM、11 nM和15 nM，可抑制多种细胞增殖，具有抗癌活性。

参考文献

1. Mahoney E, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.
2. Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392(1-2):20-8.
3. Seamon JA, et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。